Although the results from these early-stage clinical trials seemed promising for individuals with TNBC BRCA1/2 mutant disease, the stage III clinical trial OlympiAD showed no benefit of adding PARPi to the standard of care for advanced breast cancers (61). This evidence concerns the gene BRCA1 and breast cancer.